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Abstract
Background:  Ca2+-dependent activator protein 2 (CAPS2/CADPS2) is a secretory vesicle-
associated protein involved in the release of neurotrophin. We recently reported that an aberrant,
alternatively spliced CAPS2 mRNA that lacks exon 3 (CAPS2Δexon3) is detected in some patients
with autism. Splicing variations in mouse CAPS2 and their expression and functions remain unclear.
Results: In this study, we defined 31 exons in the mouse CAPS2 gene and identified six alternative
splicing variants, CAPS2a-f. CAPS2a is an isoform lacking exons 22 and 25, which encode part of
the Munc13-1-homologous domain (MHD). CAPS2b lacks exon 25. CAPS2c lacks exons 11 and 22.
CAPS2d, 2e, and 2f have C-terminal deletions from exon 14, exon 12, and exon 5, respectively. On
the other hand, a mouse counterpart of CAPS2Δexon3 was not detected in the mouse tissues
tested. CAPS2b was expressed exclusively in the brain, and the other isoforms were highly
expressed in the brain, but also in some non-neural tissues. In the brain, all isoforms showed
predominant expression patterns in the cerebellum. In the developing cerebellum, CAPS2b showed
an up-regulated expression pattern, whereas the other isoforms exhibited transiently peaked
expression patterns. CAPS2 proteins were mostly recovered in soluble fractions, but some were
present in membrane fractions, except for CAPS2c and 2f, both of which lack the PH domain,
suggesting that the PH domain is important for membrane association. In contrast to CAPS2a and
2b, CAPS2c showed slightly decreased BDNF-releasing activity, which is likely due to the C-
terminal truncation of the PH domain in CAPS2c.
Conclusion: This study indicates that, in mouse, there are six splicing variants of CAPS2 (CAPS2a-
f), and that these are subdivided into two groups: a long form containing the C-terminal MHD and
a short form lacking the C-terminal MHD. These results demonstrate that the splicing variations
correlate with their expression patterns and intracellular distribution, and affect BDNF release;
however, whether or not the short forms possess activities other than BDNF release, for example
as natural dominant-negative isoforms, remains to be determined.
Background
The Ca2+-dependent activator protein for secretion
(CAPS/CADPS) family consists of two members, CAPS1/
CADPS1 [1-3] and CAPS2/CADPS2 [4-6]. CAPS1 was
shown to play a role in the ATP-dependent priming step
of Ca2+-triggered dense-core vesicle (DCV) exocytosis by
binding to both phosphatidyl inositol 4,5-bisphosphate
and DCVs in response to Ca2+ increase [7,8]; it also inter-
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acts with the dopamine receptor [9]. A study of CAPS1-
deficient mice suggested that CAPS1 is involved in cate-
cholamine loading of DCVs in embryonic chromaffin
cells [10]. On the other hand, CAPS2 is associated with
secretory vesicles containing the neurotrophins BDNF and
NT-3 in the parallel fiber terminals of cerebellar granule
cells, and is involved in the release of BDNF and NT-3 [6].
CAPS2 is widely localized across various brain regions,
and shows overlapping distribution patterns with BDNF
in many areas [11]. Our recent studies of CAPS2-deficient
mice indicated that CAPS2 plays pivotal roles in BDNF
release, cellular phenotypes (e.g., neuronal survival and
differentiation, synapse structure and function), and
behavioral phenotypes (e.g., water-maze spatial learning,
anxiety, circadian rhythm, maternal behavior) [12,13].
The expression of an aberrant splicing variant of CAPS2 in
some patients with autism has also been reported [12].
The autistic isoform, CAPS2Δexon3, is missing exon 3,
which encodes the dynactin 1-interacting domain (DID)
[12]. Exogenously expressed CAPS2Δexon3 failed to local-
ize to axons but accumulated in somato-dendritic areas in
cultured cerebellar and cortical neurons, suggesting a pos-
sible disturbance of local CAPS2-mediated neurotrophin
release [12]. In this study, we further explore splicing var-
iations in CAPS2 and identified five additional splice iso-
forms. We characterized the expression patterns and
neurotrophin release properties of these isoforms.
Results and discussion
Using cDNA probes comprising the sequence of both
exons 4 and 5 of CAPS2, we screened a P6 mouse cerebel-
lar cDNA library for splicing variants of CAPS2. In addi-
tion to the original clone designated CAPS2a [DDBJ:
AB098623], which was identical to the one that we previ-
ously reported [6,14], we isolated five additional variants,
probably derived from full-length transcripts, designated
CAPS2b [DDBJ: AB291947], 2c [DDBJ: AB291948], 2d
[DDBJ: AB291949], 2e [DDBJ: AB291950], and 2f [DDBJ:
AB291946]. Sequence analyses against genome databases
showed that these sequences could be produced by the
different usage of the 31 exons of the CAPS2 gene (Figure
1). All splicing acceptor and donor sequences of these
clones were consistent with the AG/GT rule.
The full-length CAPS2 protein consists of the following
functional domains, as shown in Figure 2: a dynactin 1-
interacting domain (DID), a C2 domain, a pleckstrin
homology (PH) domain and a Munc13-1-homologous
domain (MHD). CAPS2b lacks only exon 25, which
encodes a part of the MHD. CAPS2a lacks two exons, 22
and 25, which encode part of the MHD sequence. CAPS2c
lacks two exons, exon 11 encoding a C-terminal part of
the PH domain, and exon 22. In contrast to these three
long isoforms (CAPS2a-c), CAPS2d, 2e and 2f have large
C-terminal large truncations from exon 14, 12, and 5,
respectively; thus, these isoforms have neither the MHD
nor the C-tail domain, which mediates the association of
CAPS with DCVs [7]. These three short isoforms (CAPS2d-
f) have an additional unique exon at their 3' end. The
shortest isoform, CAPS2f, has only the first four authentic
exons and none of the functional domains identified so
far.
All isoforms (CAPS2a-f) have exon 3, which contains the
domain interacting with p150Glued [12]. The mouse CAPS2
exon 3 coding sequence is identical to the human CAPS2
exon 3 coding sequence, which is absent in some autistic
patients. As shown in Figure 3A, no exon 3 skipping was
observed during the development of the cerebellum, from
E18 to P56, provided there were sufficient PCR cycles.
Moreover, no exon 3 skipping was observed in whole
brain, thymus, lung, heart, liver, spleen, kidney, or testis
from P7 or P21 mice (Figure 3A). These results suggest
that exon 3 skipping does not normally occur in mouse
CAPS2.
We examined the patterns of CAPS2 splicing during cere-
bellar development, by RT-PCR using specific primer sets
for each isoform. CAPS2b is the only isoform that con-
tains exon 22. Therefore, RT-PCR with a primer pair span-
ning exon 21-exon 23 resulted in a longer band (267 bp)
for CAPS2b in addition to a shorter band (147 bp) for
CAPS2a and 2c. Interestingly, there was a peak in the
expression of CAPS2a and/or 2c at P7, whereas CAPS2b
was up-regulated throughout development (Figure 3B).
The expression of CAPS2d reached a peak at P7 and
decreased thereafter, whereas that of both CAPS2e and 2f
reached a peak between P12 and P21.
Among the eight mouse tissues tested, the brain, lung, kid-
ney, and testis showed expression of all isoforms except
for CAPS2b (Figure 3C). Interestingly, expression of
CAPS2b was detectable only in the brain. Among these
isoforms, the expression level of CAPS2f was the lowest as
shown by its requiring the highest cycle number of PCR
cycles to detect it (numerals within the parenthesis of Fig-
ure 3B, C).
We next examined the cellular distribution of CAPS2 iso-
form mRNAs in P7 and P21 mouse brains by in situ
hybridization analyses. Exon 11, which contains a part of
the PH-domain coding sequence, is skipped in CAPS2c,
but is included in CAPS2a, 2b, 2d, and 2e (Figure 2). The
probe for exon 11 showed expression in the hippocampal
formation, neocortex, midbrain, and cerebellar granule
cells (Figures 4A and 4B). Exon 22, which contains a part
of the MHD coding sequence, is skipped in CAPS2a and
2c, but is included in CAPS2b (Figure 2). The probe for
exon 22 showed an expression pattern with the mostBMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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prominent level in cerebellar granule cells (Figures 4C and
4D). Expression of CAPS2d, 2e and 2f was also observed
mainly in cerebellar granule cells (Figures 4E–J). Moreo-
ver, there was no apparent difference in the expression
patterns of these isoforms in the P7 cerebellar cortex
(granule cells in the external and internal granule layers
and migrating granule cells in the molecular layer), as
shown in Figure 4K.
Nucleotide sequence and deduced amino acid sequence of mouse CAPS2 Figure 1
Nucleotide sequence and deduced amino acid sequence of mouse CAPS2. The p150Glued/dynactin 1 interacting 
domain (DID), C2 domain, PH-like domain, and Munc13-1 homologous domain (MHD) are underlined: aa 134-331, 369–452, 
494–596, and 677–1206, respectively.BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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CAPS family proteins are essentially soluble proteins, but
a fraction of them is capable of being associated with
membrane [2,5]. Therefore, we next examined the subcel-
lular fractionation patterns of these splicing variant pro-
teins, exogenously expressed in PC12 cells. All isoforms
were stably expressed in transfected PC12 cells (Figure
5A). CAPS2 isoforms containing an intact PH domain
(CAPS2a, 2b, 2d, and 2e) were recovered from the mem-
brane fraction, although a major portion of each isoform
was included in the soluble fraction. On the other hand,
CAPS2 isoforms lacking a part of the PH domain
(CAPS2c) or the entire PH domain (CAPS2f) were not
detectable in the membrane fraction, suggesting that the
PH domain has a role in the membrane association of
CAPS2 protein, as previously shown [7].
We next examined the expression of the endogenous pro-
teins produced from these splice isoform mRNAs in the
mouse brain. Immunoreactive bands corresponding to
short isoforms (CAPS2d-f) were observed at low to unde-
tectable protein levels in the mouse cerebellum (Figure
5B). In addition, the previous report showed that in non-
neural tissue such as pituitary, lung, pancreas and kidney,
only a 150 kDa band immunoreactive for CAPS2 was
detected [15]. At the mRNA level, more reaction cycles
and time were needed for the amplification of transcripts
encoding the short isoforms by RT-PCR and for the color-
imetric detection of transcripts by in situ hybridization,
respectively, indicating that the expression levels of the
genes encoding the short isoforms are very low. These
results indicate that the function of CAPS2 in vivo is appar-
ently due to the long isoforms (CAPS2a-c) rather than the
short isoforms (CAPS2d-f). However, the functional
role(s) of the short isoforms remain to be studied.
To analyze functional differences between splicing vari-
ants, we carried out a BDNF secretion assay (Figure 6). To
investigate the effect of these isoforms on BDNF releasing
activity, we exogenously expressed the three long isoforms
(CAPS2a-c) together with BDNF in PC12 cells. Short iso-
forms (CAPS2d-f) were not analyzed because of their large
C-terminal truncation (Figure 2) and very low expression
Exon and intron structures of CAPS2 splice variants Figure 2
Exon and intron structures of CAPS2 splice variants. Alternative splicing to generate CAPS2a, 2b, 2c, 2d, 2e, and 2f 
cDNAs. Represented here are the p150Glued/dynactin 1 interacting domain (DID), C2 domain, PH-like domain, Munc13-1 
homologous domain (MHD), and the C-terminal domain that mediates DCV binding (C-tail) [7]. The positions of the primers 
used in the experiments shown in Figures 3B and C are indicated by arrows. Exons used by only one isoform are shown in 
black rectangles.BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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levels in mouse brain (Figure 5B). As shown in Figure 6,
the levels of BDNF released into the culture medium in
response to high-KCl stimulation were increased approxi-
mately two-fold by the expression of CAPS2a or 2b com-
pared with cells without exogenous CAPS2 expression.
CAPS2c-expressing cells showed lower BDNF-releasing
activity than CAPS2a- or 2b-expressing cells; however,
CAPS2c-expressing cells also showed an increase in BDNF
release in response to high-KCl stimulation (Figure 6).
Moreover, there was no significant difference in basal
BDNF release between CAPS2c-expressing cells and cells
expressing either of the other two isoforms (CAPS2a and
Developmental expression pattern in cerebellum and tissue distribution of CAPS2 splice variants Figure 3
Developmental expression pattern in cerebellum and tissue distribution of CAPS2 splice variants. (A) Exon 3-
skipping in normal mice. RT-PCR analysis of CAPS2 mRNA in total RNA from developing mouse cerebella (P0, P3, P7, P12, 
P21, and P56) and various tissues (P7 and P21). An aberrant alternatively spliced CAPS2 mRNA that lacks exon 3 was previ-
ously observed in some autistic patients [12]. A single major band (502 bp) is apparent in all samples in which CAPS2 is 
expressed. A smaller band (169 bp) that would indicate skipping of exon 3 was not detected. The primers used are indicated 
on the corresponding exons by arrows. Lane M, 100-bp ladder molecular size marker (from 100 bp at the bottom to 1500 bp 
at the top). (B) The expression profile of CAPS2 isoforms in developing mouse cerebella at E18, P0, P3, P7, P12, P15, P21, and 
P56 was analyzed by RT-PCR. (C) The tissue distribution of CAPS2 isoform expression in P21 mice was analyzed by RT-PCR. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. The numbers of PCR cycles are shown in paren-
thesis.BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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Expression of CAPS2 splicing variants mRNA in P7 and P21 mouse brains Figure 4
Expression of CAPS2 splicing variants mRNA in P7 and P21 mouse brains. (A-J) In situ hybridization analysis of the 
mRNA distribution of CAPS2 isoforms in parasagittal brain sections. (A and B) Exon 11 was used as a probe for CAPS2a, 2b, 
2d, and 2e isoforms. (C and D) Exon 22 was used as a probe for the CAPS2b isoform. (E and F) The CAPS2d-specific exon 
(black rectangle in Figure 2) was used as a probe for the CAPS2d isoform. (G and H) The CAPS2e-specific exon (black rectan-
gle in Figure 2) was used as a probe for the CAPS2e isoform. (I and J) The CAPS2f-specific exon (black rectangle in Figure 2) 
was used as a probe for the CAPS2f isoform. Scale bar = 2 mm. (K) In situ hybridization analysis of the mRNA distribution of 
CAPS2 isoforms in the P7 cerebellar cortex. EGL, external granule layer; ML, molecular layer; PCL, Purkinje cell layer; IGL, 
internal granule layer. Scale bar = 50 μm.BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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2b). There was a partial deletion of the PH domain in
CAPS2c (Figure 2). The partial PH domain of PLC-gamma
1 is known to interact with a complementary partial PH-
like domain of another protein and elicit its function [16].
Therefore, it is possible that CAPS2c has some BDNF-
releasing activity, although its activity is lower than that of
intact PH domain-containing isoforms.
Interestingly, expression of the exon 22-containing iso-
form was up-regulated in the developing mouse cerebel-
lum, whereas exon 22-skipped isoforms were expressed
transiently, peaking at P7. Moreover, the exon 22-contain-
ing isoform showed higher BDNF-releasing activity than
other long isoforms (Figure 3B). On the other hand, as
described in our previous report, CAPS2 immunoreactivi-
ties are detected in both the soma and axon of cerebellar
granule cells at P7, but almost exclusively in the axon at
P21 [6]. These results suggest that the exon 22 splicing
patterns are related to high releasing activity and axonal
localization in cerebellar granule cells. CAPS2-mediated
regulation of neurotrophin actions in terms of their
releasing dose and subcellular localization may be impor-
tant for normal cerebellar development.
The splicing of exon 22 is interesting for reasons other
than the developmental differences in expression; that is,
the exon 22-containing isoform was detectable only in the
brain, whereas exon 22-skipped isoforms were widely
expressed in various tissues. Exon 22 encodes part of the
MHD, specifically a proline-rich domain (8 prolines
within 40 residues). Proline-rich motifs occurred often in
many protein-protein interaction sites, including one rec-
ognized by the Src homology 3 (SH3) domain. Our pre-
liminary screening of protein candidates that interact with
the exon 22-encoded region, by yeast two-hybrid, isolated
five candidates; however, none of these had an SH3
The subcellular distribution and expression level of CAPS2 splice variants Figure 5
The subcellular distribution and expression level of CAPS2 splice variants. (A) C-terminal HA-tagged CAPS2 iso-
forms were exogenously expressed in PC12 cells. Membrane and soluble fractions were separated as described in the Experi-
mental procedures section. An equal amount of total, soluble and membrane fractions were subjected to SDS-PAGE, followed 
by immunoblotting with an anti-HA antibody. (B) The expression profile of CAPS2 isoforms in mouse cerebella at P56 was ana-
lyzed by Western blotting. The position and size (kDa) of molecular weight markers are indicated on the left. The deduced 
molecular weight (kDa) of each isoform is indicated in parentheses on the right.BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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The functional differences between CAPS2 splice variants Figure 6
The functional differences between CAPS2 splice variants. PC12 cells were transfected with CAPS2 constructs 
together with a BDNF expression vector. The concentrations of BDNF (pg/ml) in culture media of cells with or without 50 
mM KCl stimulation were analyzed by ELISA. PC12 cells express CAPS1, another CAPS family protein, and thus showed 
increased levels of BDNF release in the presence of high K concentrations [6]. Our recent study also showed that overexpres-
sion of CAPS2 not only promotes activity-dependent, regulated release of BDNF, but also slightly increases the basal, constitu-
tive release of BDNF [12]. Data points represent the averages of values obtained from four independent experiments. The 
error bars indicate the SD. *P < 0.05, by Student's t test. The differences between the BDNF releasing activities of three iso-
forms (CAPS2a, b, and c) after 50 mM KCl stimulation were shown to be significant by one-way ANOVA analysis (P < 0.05).BMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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domain (data not shown). Future analyses of CAPS2 pro-
line-rich domain-interacting proteins will clarify the sig-
nificance of the alternative splicing of exon 22.
Conclusion
We explored the alternative splicing diversity of CAPS2
and identified six CAPS2 isoforms. The alternative splic-
ing of exon 22 (presence or absence) was associated with
a difference in tissue distribution and a developmental
expression pattern. Our study showed that an intact PH
domain is required for the association of CAPS2 with the
membrane and efficient BDNF release activity. On the
other hand, exon 3-skipping, found in autistic patients,
was not observed in the mouse tissues tested.
Methods
Animals
All experimental protocols were approved by the RIKEN
Institutional Animal Care and Use Committee.
Cloning of mouse CAPS2 splicing variants
DNA containing exons 4 and 5 of CAPS2 was used as a
probe to clone mouse CAPS2 splicing variant cDNAs.
Approximately 1 × 106 plaques of a cDNA library con-
structed from P6 cerebella of C57BL/6j mice (a kind gift
from Dr. M. E. Hatten, Rockefeller University, New York,
NY) were screened using a 32P-labeled probe. Sequencing
was performed in both directions by the dideoxy chain
termination method using [α-32P] dCTP and the BcaBest
dideoxy sequencing kit (Takara Bio, Otsu, Shiga, Japan).
RT-PCR analysis
A series of first-strand cDNAs was produced by reverse-
transcription (RT) from 20 ng of total RNA derived from
ICR mice using an oligo-dT primer. The cycling conditions
were as follows: denaturing at 94°C for 3 min, amplifica-
tion by cycles of 95°C (30 s), 60°C (30 s), and 72°C (1
min), and extension at 72°C for 5 min. Primers were as
follows. Mouse CAPS2 exon 21–23 forward primer: 5'-
GACCTGATGGAGTCTGC-3'; exon 21–23 reverse primer:
5'-CCAATGGAGATCAAAGACGAAC-3' (CAPS2b product:
267 bp; CAPS2a, c product: 147 bp); CAPS2d forward
primer: 5'-GCTGTCATTGACCCCAC-3'; CAPS2d reverse
primer: 5'-GATGAAACAACCCCAGTCAC-3' (CAPS2d
PCR product: 220 bp); CAPS2e forward primer: 5'-
CAACGCTGTTAAAGAGGGAG-3'; CAPS2e reverse
primer: 5'-GCTTCAATTTTGTGTTTTATTAAGGTTAT-
TATTTGATAATC-3' (CAPS2e PCR product: 240 bp);
CAPS2f forward primer: 5'-CTGAGTAAGGAGCAGCTC-
3'; CAPS2f reverse primer: 5'-GGCCAAGGCAGAAAGGT-
3' (CAPS2f PCR product: 225 bp). RT-PCR of mouse glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) with
the primers 5'-GCCATCAACGACCCCTTCATTGACCTC-3'
(forward primer) and 5'-GCCATGTAGGCCATGAGGTC-
CACCAC-3' (reverse primer) was used as an internal con-
trol.
In situ hybridization
DNA sequences corresponding to various exons of CAPS2
(exon 11, exon 22, CAPS2d-specific exon, CAPS2e-spe-
cific exon, and CAPS2f-specific exon) were used as tem-
plates to prepare digoxigenin-labeled antisense
riboprobes using a digoxigenin-dUTP labeling kit (Roche
Diagnostics, Indianapolis, IN, USA). Eight μm sections of
4% paraformaldehyde-fixed, paraffin-embedded P7 and
P21 mouse brains were deparaffinized and treated with a
proteinase K solution (10 ng/μl in PBS; Invitrogen,
Carlsbad, CA, USA) at room temperature for 15 min. After
acetylation, sections were incubated in a hybridization
buffer containing 500 ng/μl digoxigenin-labeled ribo-
probes, at 60°C overnight, in a humidified chamber.
Hybridized sections were washed by successive immer-
sion in 2 × SSC, 50% formamide (at 60°C for 20 min,
twice), TNE (1 mM EDTA, 0.5 M NaCl, 10 mM Tris-HCl,
pH 8.0, at 37°C for 10 min), TNE containing 20 ng/μl
RNase A (at 37°C for 30 min), 2 × SSC (at room temper-
ature for 10 min, twice), and 0.2× SSC (at 60°C for 30
min, twice). The hybridization signals were detected using
a digoxigenin detection kit (Roche diagnostics).
Subcellular fractionation
Subcellular fractionation was performed as described pre-
viously [17]. Mouse CAPS2 cDNAs were subcloned into
the pEF-BOS vector containing the EF-1α promoter [18]
and a C-terminal hemagglutinin (HA) tag to create pEF-
BOS-CAPS2-HA. PC12 cells (1 × 106 cells) transfected
with pEF-BOS-CAPS2-HA constructs, using LIPO-
FECTAMINE 2000 Reagent (Invitrogen) according to the
manufacturer's instructions, were harvested 1 day after
transfection and suspended in 1 ml of a homogenization
buffer (10 mM Tris-HCl (pH 7.5), 0.32 M sucrose, 1 mM
EDTA and a 1× cocktail of protease inhibitors) and passed
five times through a 26-gauge needle. The homogenate
was centrifuged at 1,000 × g for 10 min at 4°C. The super-
natant was further centrifuged at 100,000 × g for 1 h at
4°C and the resulting supernatant was saved as the
cytosolic fraction. The pellet was resuspended in 1 ml of
homogenization buffer (crude membrane fraction). Pro-
tein concentrations in each fraction were quantified using
bicinchoninic acid (BCA protein assay; Pierce, Rockford,
IL, USA), and equal amounts of protein were separated by
SDS-PAGE and subjected to Western blotting.
Preparation of subcellular fractions
P56 C57BL/6J male mice were sacrificed after anesthesia
with diethyl ether. Mouse cerebella were dissected and
homogenized in ice-cold homogenization buffer (50 mM
HEPES [pH 7.4], 150 mM NaCl, 10% Glycerol, 1% Triton
X-100, 5 mM EDTA, protease inhibitor cocktail) using aBMC Neuroscience 2007, 8:25 http://www.biomedcentral.com/1471-2202/8/25
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glass/Teflon homogenizer. Homogenates were centri-
fuged at 20,000 × g for 10 min at 4°C. The protein con-
centrations of lysates were quantified using a BCA protein
assay. Ten μg of protein was separated by SDS-PAGE and
subjected to Western blotting.
Antibodies
Guinea pig polyclonal anti-CAPS2 antibody raised against
the GST-tagged CAPS2 (aa 18–89) [6] and rat monoclonal
anti-HA antibody (cat. no. 1867423, Boehringer Man-
nheim, Indianapolis, IN, USA) were used for Western
blotting (used at dilution of 1:10,000 and 1:1,000, respec-
tively).
Secretion assay
Mouse BDNF cDNA was subcloned into the pEF4/Myc-
His plasmid vector containing the EF-1α promoter (Invit-
rogen) to create pEF4/Myc-His-BDNF. Mouse CAPS2
cDNA was subcloned into the pcDNA3 plasmid vector
containing the CMV promoter (Invitrogen) to create
pcDNA3-CAPS2. Transfections were carried out in 24-well
plates, using LIPOFECTAMINE 2000 Reagent (Invitrogen)
as described previously [6]. For these experiments we
applied LIPOFECTAMINE complexed with 1 μg of
pcDNA3-CAPS2 and 0.05 μg of pEF4/Myc-His-BDNF
plasmid DNAs to PC12 cells. Following 5 h of incubation
with the LIPOFECTAMINE and plasmid DNA complexes,
cells were washed and grown in normal medium. At 24 h
after transfection, PC12 cells were incubated in fresh assay
medium (DMEM containing 0.2% BSA) for 10 min. Two
different DMEMs were used: standard DMEM (11965;
Invitrogen) and high-KCl DMEM (50 mM KCl, 65 mM
NaCl based on 11965; specially ordered; Invitrogen).
Both DMEMs were fully equilibrated in a 5% CO2 atmos-
phere at 37°C before application. Culture media were col-
lected after control and high-KCl stimulation assays, and
the neurotrophin concentration (pg/ml) was measured
using the BDNF Emax ImmunoAssay System (Promega,
Madison, WI, USA) according to the manufacturer's
instructions.
Statistical analysis
Statistical analysis was performed using Statcel software
(OMS, Saitama, Japan). Data were compared using the
Student's t test or the Mann-Whitney U test according to
unequal or equal variance. Comparisons between groups
of splicing variants were made using one-way ANOVA. A
P value of <0.05 was considered statistically significant.
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